82P Stock Overview
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 82P from our risk checks.
Pacira BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.70 |
| 52 Week High | US$32.20 |
| 52 Week Low | US$10.70 |
| Beta | 0.82 |
| 11 Month Change | 6.37% |
| 3 Month Change | 29.46% |
| 1 Year Change | -30.42% |
| 33 Year Change | -63.05% |
| 5 Year Change | -59.86% |
| Change since IPO | 249.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 82P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 8.4% | -1.0% | 0.2% |
| 1Y | -30.4% | -19.3% | 8.5% |
Return vs Industry: 82P underperformed the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 82P underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 82P volatility | |
|---|---|
| 82P Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 82P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 82P's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 712 | Frank Lee | www.pacira.com |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
Pacira BioSciences, Inc. Fundamentals Summary
| 82P fundamental statistics | |
|---|---|
| Market cap | €778.17m |
| Earnings (TTM) | -€87.13m |
| Revenue (TTM) | €667.37m |
1.2x
P/S Ratio-8.9x
P/E RatioIs 82P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 82P income statement (TTM) | |
|---|---|
| Revenue | US$694.96m |
| Cost of Revenue | US$255.38m |
| Gross Profit | US$439.58m |
| Other Expenses | US$530.31m |
| Earnings | -US$90.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 63.25% |
| Net Profit Margin | -13.06% |
| Debt/Equity Ratio | 78.4% |
How did 82P perform over the long term?
See historical performance and comparison